文献速递冠心病心力衰竭与心肌病

经皮跨瓣膜微轴流泵在心脏病学中的应用

Percutaneous Transvalvular Microaxial Flow Pump Support in Cardiology.
PubMed 文献 · Circulation · 2022-04-18

Impella装置是一种经皮跨瓣膜微轴流泵,目前用于心源性休克、左心室卸载、高危PCI、室速消融及右心衰治疗。观察性研究和部分随机试验显示其可增加前向血流、平均动脉压、心输出量、外周组织灌注和冠脉血流,但出血和缺血并发症发生率分别高达44%和18%,溶血达32%,卒中达13%。仅有的两项小型且把握度不足的随机对照试验比较Impella与主动脉内球囊反搏,未显示死亡率改善。

要点

  • Impella用于心源性休克、左室卸载、高危PCI、室速消融和右心衰。
  • 出血并发症高达44%,缺血并发症18%,溶血32%,卒中13%。
  • 两项小型RCT未显示Impella较IABP改善心源性休克死亡率。

核心结论

  • Impella增加前向血流和血流动力学指标,但并发症发生率高。
  • 目前缺乏大型充分把握度RCT证实其对结局的影响。

研究设计与样本

  • 综述性文章,总结Impella装置的临床应用、血流动力学效应、并发症及随机试验证据。

主要发现

  • 观察性研究和部分随机试验显示Impella辅助前向血流增加平均动脉压、心输出量、外周组织灌注和冠脉血流。
  • 出血和缺血并发症发生率分别高达44%和18%。
  • 溶血报告率高达32%,卒中高达13%。
  • 两项小型且把握度不足的RCT比较Impella与IABP,未显示死亡率改善。

关键数值与推荐

  • 常用Impella CP装置需14F股动脉大口径通路。
  • Impella使用需抗凝。

临床怎么用

  • Impella可用于心源性休克、左室卸载、高危PCI、室速消融和右心衰。
  • 使用中需警惕出血、缺血、溶血和卒中并发症。
  • 当前证据不足以确定Impella对结局的影响,需等待正在进行的RCT结果。

局限性

  • 缺乏大型充分把握度RCT评估Impella对结局和并发症的影响。
  • 现有两项心源性休克RCT样本量小且把握度不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Impella device (Impella, Abiomed, Danvers, MA) is a percutaneous transvalvular microaxial flow pump that is currently used for (1) cardiogenic shock, (2) left ventricular unloading (combination of venoarterial extracorporeal membrane oxygenation and Impella concept), (3) high-risk percutaneous coronary interventions, (4) ablation of ventricular tachycardia, and (5) treatment of right ventricular failure. Impella-assisted forward blood flow increased mean arterial pressure and cardiac output, peripheral tissue perfusion, and coronary blood flow in observational studies and some randomized trials. However, because of the need for large-bore femoral access (14 F for the commonly used Impella CP device) and anticoagulation, the incidences of bleeding and ischemic complications are as much as 44% and 18%, respectively. Hemolysis is reported in as many as 32% of patients and stroke in as many as 13%. Despite the rapidly growing use of the Impella device, there are still insufficient data on its effect on outcome and complications on the basis of large, adequately powered randomized controlled trials. The only 2 small and also underpowered randomized controlled trials in cardiogenic shock comparing Impella versus intra-aortic balloon pump did not show improved mortality. Several larger randomized controlled trials are currently recruiting patients or are in preparation in cardiogenic shock (DanGer Shock [Danish-German Cardiogenic Shock Trial; NCT01633502]), left ventricular unloading (DTU-STEMI [Door-To-Unload in ST-Segment-Elevation Myocardial Infarction; NCT03947619], UNLOAD ECMO [Left Ventricular Unloading to Improve Outcome in Cardiogenic Shock Patients on VA-ECMO], and REVERSE [A Prospective Randomised Trial of Early LV Venting Using Impella CP for Recovery in Patients With Cardiogenic Shock Managed With VA ECMO; NCT03431467]) and high-risk percutaneous coronary intervention (PROTECT IV [Impella-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function; NCT04763200]).

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Lüsebrink, Kellnar, Krieg, et al. Percutaneous Transvalvular Microaxial Flow Pump Support in Cardiology. Circulation. 2022. PMID: 35436135. doi:10.1161/CIRCULATIONAHA.121.058229

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。